[ad_1]
San Jose, California with Stephen Finch, December 5, 2021 /PRNewswire/ – KDx Diagnostics, Inc. (KDx) and Lister Hospital (East Hertfordshire NHS Trust Fund), Stevenage, United Kingdom, Announced today at U.K (UK) URO17 of KDx® A test to detect bladder cancer. This non-invasive urine test for bladder cancer is very sensitive to identify hematuria and bladder cancer in patients with recurrent bladder cancer during the post-treatment monitoring period.
More than 197,000 newly diagnosed cases of bladder cancer Europe, And 430,000 cases worldwide, and 81,000 cases in the United States alone. Accurately detecting new bladder cancer is difficult and expensive, and requires invasive camera-based testing methods. What’s exciting is that KDx’s URO17® In a number of peer-reviewed studies, the test proved 100% sensitivity and more than 90% specificity in detecting bladder cancer.
“We are very happy to have a non-invasive URO17® Tests available in the UK to determine with high confidence whether a patient has bladder cancer. Tests show URO17® Urine test can detect the presence or absence of bladder cancer with high sensitivity. We are confident to apply URO17® Can significantly improve patient care in the UK in clinical practice,” Said Nan Weijin, PhD, CEO and CTO of KDx.
“Because of the high recurrence rate, bladder cancer is a cancer that is expensive to treat and usually requires invasive procedures to diagnose. KDx’s URO17® Urine tests are revolutionizing the detection, management, and treatment of bladder cancer.We are very happy that Lister Hospital is in Stevenage Yes…
The full story can be found on Benzinga.com
[ad_2]
Source link
